Vagus Nerve Stimulation

When researchers at ACR Convergence 2024 presented positive data from the RESET RA study regarding vagus nerve stimulation in rheumatoid arthritis, it represented the latest milestone on a long and unpredictable journey for the treatment.

SAN DIEGO — Vagus nerve stimulation may represent a “novel therapeutic option” for patients with rheumatoid arthritis, according to data presented at the 2024 Congress of Clinical Rheumatology West.

The FDA has granted investigational device exemption to a clinical-stage health care firm for its proprietary neuroimmune modulation platform for individuals with relapsing-remitting MS, according to the manufacturer.

In this video, Maria Danila, MD, discusses recent advancements in rheumatoid arthritis.

Healio spoke with Joshua Baker, MD, about the importance of early treatment of rheumatoid arthritis, the unmet needs of patients with rheumatoid arthritis, common comorbid conditions associated with rheumatoid arthritis and more.

Vagus nerve stimulation surgeries were relatively safe, with complication rates low but differing depending on the type of procedure and presence of complications, researchers reported in Brain and Spine.

The FDA has approved breakthrough device designation for a novel neuroimmune modulation platform for those with relapsing-remitting multiple sclerosis, according to the manufacturer.

Surgical procedures targeting vagus nerve stimulation for those with drug-resistant epilepsy are generally safe with low incidence and rate of complications, according to research from Brain and Spine.

In early September, the FDA granted Breakthrough Device Designation and cleared the SAINT Neuromodulation System for treatment-resistant depression, or TRD.

Commercial-stage bioelectronic medicine company electroCore Inc. announced its noninvasive vagus nerve stimulation intervention for migraine prevention reduced the number of monthly headache days.